Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:PETX

Aratana Therapeutics (PETX) Stock Price, News & Analysis

Aratana Therapeutics logo

About Aratana Therapeutics Stock (NASDAQ:PETX)

Advanced Chart

Key Stats

Today's Range
$4.92
$4.92
50-Day Range
$4.92
$4.92
52-Week Range
$3.30
$7.16
Volume
N/A
Average Volume
1.03 million shs
Market Capitalization
$241.08 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive PETX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aratana Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PETX Stock News Headlines

PETX_old Historical Data
This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.
5 Stocks Under $10 to Trade for Big Breakouts
Aratana (PETX) Tops Q3 Earnings and Revenue Estimates
See More Headlines

PETX Stock Analysis - Frequently Asked Questions

Aratana Therapeutics Inc (NASDAQ:PETX) announced its quarterly earnings results on Thursday, November, 1st. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.03. The biopharmaceutical company had revenue of $21.56 million for the quarter, compared to analysts' expectations of $5.70 million. Aratana Therapeutics had a negative trailing twelve-month return on equity of 12.99% and a negative net margin of 33.47%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Aratana Therapeutics investors own include Celldex Therapeutics (CLDX), Corcept Therapeutics (CORT), Synergy Pharmaceuticals (SGYP), Exelixis (EXEL), Pieris Pharmaceuticals (PIRS), ACADIA Pharmaceuticals (ACAD) and Corbus Pharmaceuticals (CRBP).

Company Calendar

Last Earnings
11/01/2018
Today
7/05/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:PETX
Fax
N/A
Employees
83
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$14.72 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$35.41 million
Price / Cash Flow
N/A
Book Value
$2.07 per share
Price / Book
2.38

Miscellaneous

Free Float
N/A
Market Cap
$241.08 million
Optionable
Optionable
Beta
1.40
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:PETX) was last updated on 7/5/2025 by MarketBeat.com Staff
From Our Partners